VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q85809986 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233040.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q85809986‏
024 ‎‡a 0000-0001-5258-7921‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q85809986‏
100 0 ‎‡a Mariana P C Ribeiro‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Mariana P C Ribeiro‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer‏
670 ‎‡a Author's Atypical cyclins: the extended family portrait‏
670 ‎‡a Author's Comprehensive and quantitative analysis of G1 cyclins. A tool for studying the cell cycle‏
670 ‎‡a Author's Effects of all-trans-retinoic acid on the permeability transition and bioenergetic functions of rat liver mitochondria in combination with endoxifen.‏
670 ‎‡a Author's Interplay between estrogen and retinoid signaling in breast cancer--current and future perspectives‏
670 ‎‡a Author's Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?‏
670 ‎‡a Author's Live fast, die soon: cell cycle progression and lifespan in yeast cells‏
670 ‎‡a Author's Mitochondria: the gateway for tamoxifen-induced liver injury.‏
670 ‎‡a Author's Phosphate: from stardust to eukaryotic cell cycle control.‏
670 ‎‡a Author's Phosphoregulation of the oncogenic protein regulator of cytokinesis 1‏
670 ‎‡a Author's Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex‏
670 ‎‡a Author's Polyphosphate is a key factor for cell survival after DNA damage in eukaryotic cells.‏
670 ‎‡a Author's Polyphosphate: popping up from oblivion‏
670 ‎‡a Author's Rethinking tamoxifen in the management of melanoma: New answers for an old question‏
670 ‎‡a Author's The activation of the G protein-coupled estrogen receptor‏
670 ‎‡a Author's The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells‏
670 ‎‡a Author's The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.‏
670 ‎‡a Author's The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency.‏
670 ‎‡a Author's The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration‏
670 ‎‡a Author's The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.‏
909 ‎‡a (orcid) 0000000152587921‏ ‎‡9 1‏
919 ‎‡a systematicanalysisoforphancyclinsrevealscntd2asanewoncogenicdriverinlungcancer‏ ‎‡A A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer‏ ‎‡9 1‏
919 ‎‡a comprehensiveandquantitativeanalysisofg1cyclinsatoolforstudyingthecellcycle‏ ‎‡A Comprehensive and quantitative analysis of G1 cyclins. A tool for studying the cell cycle‏ ‎‡9 1‏
919 ‎‡a effectsofalltransretinoicacidonthepermeabilitytransitionandbioenergeticfunctionsofratlivermitochondriaincombinationwithendoxifen‏ ‎‡A Effects of all-trans-retinoic acid on the permeability transition and bioenergetic functions of rat liver mitochondria in combination with endoxifen.‏ ‎‡9 1‏
919 ‎‡a interplaybetweenestrogenandretinoidsignalinginbreastcancercurrentandfutureperspectives‏ ‎‡A Interplay between estrogen and retinoid signaling in breast cancer--current and future perspectives‏ ‎‡9 1‏
919 ‎‡a ionotropicglutamatereceptorantagonistsandcancertherapytimetothinkoutofthebox‏ ‎‡A Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box?‏ ‎‡9 1‏
919 ‎‡a livefastdiesooncellcycleprogressionandlifespaninyeastcells‏ ‎‡A Live fast, die soon: cell cycle progression and lifespan in yeast cells‏ ‎‡9 1‏
919 ‎‡a mitochondriathegatewayfortamoxifeninducedliverinjury‏ ‎‡A Mitochondria: the gateway for tamoxifen-induced liver injury.‏ ‎‡9 1‏
919 ‎‡a phosphatefromstardusttoeukaryoticcellcyclecontrol‏ ‎‡A Phosphate: from stardust to eukaryotic cell cycle control.‏ ‎‡9 1‏
919 ‎‡a phosphoregulationoftheoncogenicproteinregulatorofcytokinesis1‏ ‎‡A Phosphoregulation of the oncogenic protein regulator of cytokinesis 1‏ ‎‡9 1‏
919 ‎‡a phosphoregulationoftheoncogenicproteinregulatorofcytokinesis1prc1bytheatypicalcdk16ccnycomplex‏ ‎‡A Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex‏ ‎‡9 1‏
919 ‎‡a polyphosphatepoppingupfromoblivion‏ ‎‡A Polyphosphate: popping up from oblivion‏ ‎‡9 1‏
919 ‎‡a rethinkingtamoxifeninthemanagementofmelanomanewanswersforanoldquestion‏ ‎‡A Rethinking tamoxifen in the management of melanoma: New answers for an old question‏ ‎‡9 1‏
919 ‎‡a activationofthegproteincoupledestrogenreceptor‏ ‎‡A The activation of the G protein-coupled estrogen receptor‏ ‎‡9 1‏
919 ‎‡a activationofthegproteincoupledestrogenreceptorgperinhibitstheproliferationofmousemelanomak1735m2cells‏ ‎‡A The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells‏ ‎‡9 1‏
919 ‎‡a antiestrogen4hydroxytamoxifenprotectsagainstisotretinoininducedpermeabilitytransitionandbioenergeticdysfunctionoflivermitochondriacomparisonwithtamoxifen‏ ‎‡A The antiestrogen 4-hydroxytamoxifen protects against isotretinoin-induced permeability transition and bioenergetic dysfunction of liver mitochondria: comparison with tamoxifen.‏ ‎‡9 1‏
919 ‎‡a antiestrogenendoxifenprotectsratlivermitochondriafrompermeabilitytransitionporeopeningandoxidativestressatconcentrationsthatdonotaffectthephosphorylationefficiency‏ ‎‡A The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency.‏ ‎‡9 1‏
919 ‎‡a atypicalcyclincntd2promotescoloncancercellproliferationandmigration‏ ‎‡A The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration‏ ‎‡9 1‏
919 ‎‡a combinationofglutamatereceptorantagonistmk801withtamoxifenanditsactivemetabolitespotentiatestheirantiproliferativeactivityinmousemelanomak1735m2cells‏ ‎‡A The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.‏ ‎‡9 1‏
919 ‎‡a atypicalcyclinstheextendedfamilyportrait‏ ‎‡A Atypical cyclins: the extended family portrait‏ ‎‡9 1‏
919 ‎‡a polyphosphateisakeyfactorforcellsurvivalafterdnadamageineukaryoticcells‏ ‎‡A Polyphosphate is a key factor for cell survival after DNA damage in eukaryotic cells.‏ ‎‡9 1‏
996 ‎‡2 SUDOC|170319067
996 ‎‡2 LC|n 2012213335
996 ‎‡2 BLBNB|000290987
996 ‎‡2 BLBNB|001579028
996 ‎‡2 PTBNP|1290927
996 ‎‡2 PLWABN|9813293491905606
996 ‎‡2 PTBNP|67293
996 ‎‡2 ISNI|0000000505497359
996 ‎‡2 LC|n 79010096
996 ‎‡2 ISNI|0000000063301047
996 ‎‡2 ISNI|0000000067550542
996 ‎‡2 DNB|1046539582
996 ‎‡2 BLBNB|000484132
996 ‎‡2 ISNI|0000000120507341
996 ‎‡2 PTBNP|89804
996 ‎‡2 PTBNP|149618
996 ‎‡2 BLBNB|000311398
996 ‎‡2 PTBNP|1406802
996 ‎‡2 ISNI|0000000428207521
996 ‎‡2 ISNI|0000000116124735
996 ‎‡2 PTBNP|1674875
996 ‎‡2 ISNI|0000000053770392
996 ‎‡2 DNB|1056708093
996 ‎‡2 PTBNP|1484997
996 ‎‡2 PTBNP|718073
996 ‎‡2 PTBNP|38457
996 ‎‡2 DNB|1157214304
996 ‎‡2 PTBNP|255652
996 ‎‡2 PTBNP|997289
996 ‎‡2 LC|n 84134380
996 ‎‡2 ISNI|0000000068800531
996 ‎‡2 NTA|158680332
996 ‎‡2 NTA|23635891X
996 ‎‡2 ISNI|0000000428320866
996 ‎‡2 PTBNP|228058
996 ‎‡2 ISNI|0000000424600713
996 ‎‡2 ISNI|0000000033432062
996 ‎‡2 BLBNB|001442092
996 ‎‡2 BNF|16745872
996 ‎‡2 PTBNP|1915332
996 ‎‡2 BLBNB|000266524
996 ‎‡2 LC|no2017158721
996 ‎‡2 BLBNB|000182348
996 ‎‡2 ISNI|0000000046078971
996 ‎‡2 ISNI|000000035903251X
996 ‎‡2 ISNI|0000000068306744
996 ‎‡2 LC|no2005000355
996 ‎‡2 PTBNP|1557893
996 ‎‡2 PTBNP|1318766
996 ‎‡2 LC|no2006112870
996 ‎‡2 ISNI|0000000114101257
996 ‎‡2 PTBNP|1241204
996 ‎‡2 ISNI|000000005940297X
996 ‎‡2 BLBNB|000581542
996 ‎‡2 SUDOC|033192529
996 ‎‡2 PTBNP|1742289
996 ‎‡2 ISNI|0000000070230494
996 ‎‡2 BIBSYS|90561709
996 ‎‡2 PTBNP|1401342
996 ‎‡2 ISNI|0000000070517057
996 ‎‡2 RERO|A003510538
996 ‎‡2 PTBNP|212663
996 ‎‡2 PTBNP|1358623
996 ‎‡2 BLBNB|000458530
996 ‎‡2 DNB|1189687453
996 ‎‡2 PTBNP|1189983
996 ‎‡2 BLBNB|000305643
996 ‎‡2 BLBNB|000431403
996 ‎‡2 NUKAT|n 2022068522
996 ‎‡2 ISNI|0000000036193108
996 ‎‡2 BLBNB|000487999
996 ‎‡2 DNB|1056639490
996 ‎‡2 BLBNB|000583696
996 ‎‡2 PTBNP|1767334
996 ‎‡2 PTBNP|1616736
996 ‎‡2 ISNI|0000000070228853
996 ‎‡2 DNB|1053075103
996 ‎‡2 PLWABN|9813281037005606
996 ‎‡2 ISNI|0000000069798787
996 ‎‡2 LIH|LNB:C_h_47;=BM
996 ‎‡2 PTBNP|1380245
996 ‎‡2 BLBNB|000322825
996 ‎‡2 BLBNB|000332705
996 ‎‡2 ISNI|0000000069830126
996 ‎‡2 BLBNB|000332707
996 ‎‡2 BLBNB|000332701
996 ‎‡2 BLBNB|000332700
996 ‎‡2 BLBNB|000332703
996 ‎‡2 LC|nb2004303060
996 ‎‡2 SUDOC|138471665
996 ‎‡2 BLBNB|000332709
996 ‎‡2 BLBNB|000386880
996 ‎‡2 ISNI|0000000068119340
996 ‎‡2 ISNI|0000000072774145
996 ‎‡2 J9U|987007261051305171
996 ‎‡2 BLBNB|000350630
996 ‎‡2 BLBNB|000403225
996 ‎‡2 BLBNB|000435708
996 ‎‡2 BLBNB|000480540
996 ‎‡2 DNB|105330143X
996 ‎‡2 PTBNP|193738
996 ‎‡2 BLBNB|000477528
996 ‎‡2 BNF|17985625
996 ‎‡2 ISNI|0000000069786866
996 ‎‡2 PTBNP|798494
996 ‎‡2 J9U|987007266908505171
996 ‎‡2 ISNI|0000000070394800
996 ‎‡2 BLBNB|001415849
996 ‎‡2 BLBNB|000375882
996 ‎‡2 BLBNB|000352631
996 ‎‡2 DNB|1057442321
996 ‎‡2 ISNI|0000000041431764
996 ‎‡2 LC|no2002103728
996 ‎‡2 ISNI|0000000067669308
996 ‎‡2 ISNI|0000000043865531
996 ‎‡2 PTBNP|1492979
996 ‎‡2 ISNI|0000000070131859
996 ‎‡2 ISNI|0000000030314976
996 ‎‡2 BLBNB|000562118
996 ‎‡2 ISNI|0000000476753738
996 ‎‡2 ISNI|0000000014285044
996 ‎‡2 DNB|1056187913
996 ‎‡2 SUDOC|145478246
996 ‎‡2 PTBNP|218866
996 ‎‡2 PTBNP|43578
996 ‎‡2 ISNI|0000000068209012
996 ‎‡2 PTBNP|1320849
996 ‎‡2 DNB|1167532562
996 ‎‡2 PTBNP|1418341
996 ‎‡2 DNB|1047962152
996 ‎‡2 BLBNB|000424600
996 ‎‡2 PTBNP|40020
996 ‎‡2 LC|no2013023157
996 ‎‡2 ISNI|0000000070803205
996 ‎‡2 ISNI|0000000067343754
996 ‎‡2 NUKAT|n 2019223771
996 ‎‡2 PTBNP|177351
996 ‎‡2 PTBNP|1382281
996 ‎‡2 PTBNP|1742531
996 ‎‡2 DNB|1074946162
996 ‎‡2 PTBNP|57983
996 ‎‡2 PTBNP|35433
996 ‎‡2 ISNI|0000000067680478
996 ‎‡2 NUKAT|n 2017078992
996 ‎‡2 ISNI|0000000044186506
996 ‎‡2 LC|n 82055755
996 ‎‡2 ISNI|0000000367623651
996 ‎‡2 DNB|1053819838
996 ‎‡2 NSK|000320255
996 ‎‡2 ISNI|0000000070126419
996 ‎‡2 BLBNB|000990080
996 ‎‡2 LC|n 91077647
996 ‎‡2 ISNI|0000000382949668
996 ‎‡2 PTBNP|9962
996 ‎‡2 BLBNB|000569010
996 ‎‡2 BNF|15884168
996 ‎‡2 ISNI|0000000070319093
996 ‎‡2 ISNI|0000000066492811
996 ‎‡2 LC|no2006109523
996 ‎‡2 ISNI|0000000428233228
996 ‎‡2 PTBNP|1449345
996 ‎‡2 ISNI|0000000070321644
996 ‎‡2 PTBNP|213013
996 ‎‡2 BLBNB|000234062
996 ‎‡2 PTBNP|1593036
996 ‎‡2 NTA|099982129
996 ‎‡2 PTBNP|96510
996 ‎‡2 JPG|500067122
996 ‎‡2 PTBNP|1591319
996 ‎‡2 LC|no2002063321
996 ‎‡2 ISNI|0000000069424742
996 ‎‡2 NUKAT|n 2010075961
996 ‎‡2 BLBNB|000276519
996 ‎‡2 PTBNP|120511
996 ‎‡2 ISNI|0000000495739288
996 ‎‡2 PTBNP|1292360
996 ‎‡2 DNB|1057115002
996 ‎‡2 ISNI|0000000069998105
996 ‎‡2 BLBNB|000292701
996 ‎‡2 DNB|1333383355
996 ‎‡2 LC|no 99084454
996 ‎‡2 BLBNB|001520873
996 ‎‡2 ISNI|0000000070818167
996 ‎‡2 RERO|A017164221
996 ‎‡2 LC|no2011164335
996 ‎‡2 ISNI|0000000099484770
996 ‎‡2 PTBNP|921419
996 ‎‡2 SUDOC|087225581
996 ‎‡2 BLBNB|000219703
996 ‎‡2 DNB|1044330163
996 ‎‡2 PTBNP|1423134
996 ‎‡2 RERO|A003368809
996 ‎‡2 BLBNB|000553716
996 ‎‡2 SUDOC|144231425
996 ‎‡2 SUDOC|163697213
996 ‎‡2 PTBNP|1229591
996 ‎‡2 LC|n 97092629
996 ‎‡2 LC|nr2001015104
996 ‎‡2 ISNI|0000000069890583
996 ‎‡2 PTBNP|1019698
996 ‎‡2 ISNI|0000000035448156
996 ‎‡2 BLBNB|000531523
996 ‎‡2 LC|n 2020042460
996 ‎‡2 DNB|1043624473
996 ‎‡2 ISNI|0000000029560133
996 ‎‡2 PTBNP|999607
996 ‎‡2 BLBNB|000552561
996 ‎‡2 SUDOC|068896018
996 ‎‡2 PTBNP|1182994
996 ‎‡2 ISNI|0000000030471891
996 ‎‡2 BLBNB|000489273
996 ‎‡2 LC|nb2016011668
996 ‎‡2 BLBNB|000440647
996 ‎‡2 PTBNP|107321
996 ‎‡2 BNF|12137064
996 ‎‡2 ISNI|0000000023736919
996 ‎‡2 PTBNP|107324
996 ‎‡2 LC|n 86077751
996 ‎‡2 BLBNB|000990883
996 ‎‡2 PTBNP|107329
996 ‎‡2 LC|n 2023255449
996 ‎‡2 PTBNP|1742132
996 ‎‡2 ISNI|0000000070230291
996 ‎‡2 SUDOC|156413582
996 ‎‡2 PTBNP|1021320
996 ‎‡2 LC|n 95922577
996 ‎‡2 DNB|1212688651
996 ‎‡2 ISNI|000000004363248X
996 ‎‡2 LC|no2002016377
996 ‎‡2 PTBNP|1700683
996 ‎‡2 SUDOC|159714400
996 ‎‡2 DNB|1060659751
996 ‎‡2 ISNI|0000000116747844
996 ‎‡2 LC|n 94033775
996 ‎‡2 J9U|987007271811305171
996 ‎‡2 BNF|13478965
996 ‎‡2 BLBNB|000587696
996 ‎‡2 PTBNP|967726
996 ‎‡2 LC|n 2022252093
996 ‎‡2 NUKAT|n 2008127261
996 ‎‡2 PTBNP|1018405
996 ‎‡2 CAOONL|ncf11741624
996 ‎‡2 DNB|1179978749
996 ‎‡2 RERO|A023090326
996 ‎‡2 LC|n 88072145
996 ‎‡2 PTBNP|193169
996 ‎‡2 LIH|LNB:C_u_DQ;=B_j_
996 ‎‡2 ISNI|0000000081007052
996 ‎‡2 RERO|A005923523
996 ‎‡2 ISNI|0000000068718394
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏